Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
DJ Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
By Chris Wack
Veru Inc. said Monday it has engaged Morgan Stanley & Co. as a financial advisor to assist it in pursuing strategic alternatives regarding its legacy FC2 Female Condom/FC2 Internal Condom business.
The biopharmaceutical company said it considers now a good time to consider alternatives for the business, with the last two consecutive quarters for its FHC business having set records in terms of revenues and profit.
Veru said that with the potential for five registration clinical trials in calendar year 2021, it has transformed itself into a late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC business isn't as strong as it once was.
The company said it is open to exploring the right kind of strategic transaction for the FHC business with a view toward the best, long-term interests of its shareholders, which may include continuing to operate the FHC business.
Veru shares were up 8% to $13.25 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 08, 2021 09:18 ET (14:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
DJ Veru增加财务顾问为女性健康业务寻找替代方案
By Chris Wack
克里斯·瓦克(Chris Wack)著
Veru Inc. said Monday it has engaged Morgan Stanley & Co. as a financial advisor to assist it in pursuing strategic alternatives regarding its legacy FC2 Female Condom/FC2 Internal Condom business.
维鲁公司周一表示，它已聘请摩根士丹利公司作为财务顾问，协助其寻找传统的FC2女用避孕套/FC2内部避孕套业务的战略选择。
The biopharmaceutical company said it considers now a good time to consider alternatives for the business, with the last two consecutive quarters for its FHC business having set records in terms of revenues and profit.
这家生物制药公司表示，它认为现在是考虑该业务替代方案的好时机，其FHC业务连续两个季度在收入和利润方面创下纪录。
Veru said that with the potential for five registration clinical trials in calendar year 2021, it has transformed itself into a late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC business isn't as strong as it once was.
Veru表示，随着2021年有可能进行5项注册临床试验，该公司已转型为一家后期临床生物制药公司，因此与FHC业务的战略契合度不像以前那么强。
The company said it is open to exploring the right kind of strategic transaction for the FHC business with a view toward the best, long-term interests of its shareholders, which may include continuing to operate the FHC business.
该公司表示，它愿意为FHC业务探索合适的战略交易，以期实现股东的最佳长期利益，其中可能包括继续运营FHC业务。
Veru shares were up 8% to $13.25 in premarket trading.
Veru股价在盘前交易中上涨8%，至13.25美元。
Write to Chris Wack at chris.wack@wsj.com
写信给克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
March 08, 2021 09:18 ET (14:18 GMT)
2021年3月8日09：18美国东部时间(格林尼治标准时间14：18)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧